Sign In
Buy PFE
$26.04
+0.345 (+1.34%)
At Close: Jun 05, 2026
Time To Buy These 3 Extremely Undervalued Stocks
01:14pm, Monday, 19'th Aug 2024
Despite broader market indexes reaching new highs, driven mainly by tech stock momentum, many companies have faced plummeting valuations due to worsening macroeconomic conditions.
Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters
10:25am, Monday, 19'th Aug 2024
Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
10:00am, Monday, 19'th Aug 2024
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer Is Staking Its Turnaround on Cancer Drugs
05:30am, Monday, 19'th Aug 2024
BOTHELL, Wash.—At a recent company town hall here, Pfizer's cancer-business chief looked over some 100 scientists, marketers and other staffers who had just joined the giant drugmaker through a $43
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
04:07am, Monday, 19'th Aug 2024
Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve
Is Pfizer Stock Ready to Bounce Back?
06:02am, Sunday, 18'th Aug 2024
Pfizer's revenue grew on a year-over-year basis for the first time in a while. Though a recent acquisition helped, there were other factors that contributed.
3 Dividend Stocks to Double Up On Right Now
09:05am, Saturday, 17'th Aug 2024
Pfizer has a promising pipeline of drugs in development -- tackling cancers and more. Medtronic's 200-plus clinical trials may yield some big revenue generators.
10 Great Dividend Stocks For The Next 10 Years
09:00am, Saturday, 17'th Aug 2024
The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
05:45am, Saturday, 17'th Aug 2024
D.R. Horton should have both near-term and long-term catalysts. Energy Transfer's distribution gives it a big advantage in generating attractive total returns.
Why Pfizer Stock Slumped on Friday
06:38pm, Friday, 16'th Aug 2024
Its combination COVID-19/influenza vaccine fell short of one of its endpoints in a late-stage clinical trial. The U.S. pharmaceutical giant is developing the jab with its European partner BioNTech.
Pfizer Dividend Yield Pushes Past 6%
05:02pm, Friday, 16'th Aug 2024
In trading on Friday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.85 on the day. Dividends are p
Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints
02:28pm, Friday, 16'th Aug 2024
Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined
Pfizer, BioNTech COVID-19-flu combination drug meets 1 of 2 trial objectives
07:01am, Friday, 16'th Aug 2024
Pfizer Inc. PFE, -0.59% and BioNTech SE BNTX, +2.83% said Friday a Phase 3 trial of their COVID-19-influenza vaccine candidate met one of its two objectives. The companies said the candidate showed �
Was Q2 The Turning Point For Pfizer Stock?
07:00am, Friday, 16'th Aug 2024
With Pfizer's sales rising in Q2, despite falling sales of Covid-19 products, we think that it may well be the turning point for Pfizer stock. It has seen a decline of 15% from levels of $35 in early
Pfizer, BioNtech say combined flu-COVID vaccine misses a main goal of Phase 3 trial
06:51am, Friday, 16'th Aug 2024
Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and
